Published in
Oxford University Press, Clinical Infectious Diseases, 3(59), p. 435-445, 2014
DOI: 10.1093/cid/ciu283
Links
- Oxford University Press
- ORCID
- ORCID
- [hdl.handle.net]
- [fieldresearch.msf.org] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net]
Tools
Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial
Journal article published in 2014 by
Olivier Marcy,
Didier Laureillard,
Yoann Madec 
,
Sarin Chan,
Charles Mayaud,
Laurence Borand,
Narom Prak,
Chindamony Kim,
Kim Khemarin Lak,
Chanroeurn Hak,
Bunnet Dim,
Thim Sok,
Jean-François Delfraissy,
Anne E. Goldfeld,
François-Xavier Blanc
,
Sarin Chan,
Charles Mayaud,
Laurence Borand,
Narom Prak,
Chindamony Kim,
Kim Khemarin Lak,
Chanroeurn Hak,
Bunnet Dim,
Thim Sok,
Jean-François Delfraissy,
Anne E. Goldfeld,
François-Xavier Blanc
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Shortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency virus (HIV)-infected patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to further enhance survival.